Innovative Virtual Event on Eversense 365 by Senseonics
Senseonics Holdings, Inc. (NYSE American: SENS), a pioneering medical technology company, has recently announced an innovative virtual event focused on the Eversense 365 Continuous Glucose Monitoring (CGM) system. This highly anticipated event is set to take place on a future date, and it invites healthcare professionals and diabetes management enthusiasts to learn about the groundbreaking advancements in CGM technology.
Highlights of Eversense 365
The Eversense 365 system represents a remarkable leap in diabetes management technology, earning recent clearance from the U.S. Food and Drug Administration. This makes it the world's first CGM system capable of providing continuous glucose measurements for an entire year. This extended monitoring capability differentiates it significantly from conventional options, providing patients with greater reliability and convenience in managing their diabetes.
Expert Insights at the Event
This virtual gathering will feature key opinion leaders in the field, including health professionals who specialize in diabetes management. Attendees will gain insights from experts on how the Eversense 365 system is being integrated into clinical practice, its benefits for Type 1 and Type 2 diabetes patients aged 18 years and older, and the overarching commercial collaboration with esteemed healthcare systems.
Live Q&A Session
Participants can also look forward to an interactive question and answer session that will follow the primary presentations, allowing for a deeper understanding of the system's capabilities and applications. This format aims to encourage dialogue between experts and attendees, fostering a collaborative atmosphere for discussion and inquiry.
The Importance of CGM Technology
Continuous Glucose Monitoring represents a significant advancement in diabetes care, ensuring that patients keep their glucose levels in check more efficiently. The Eversense 365 offers a small sensor that is implanted subcutaneously and communicates with a transmitter worn on the body, sending glucose readings automatically to a mobile application every five minutes. This technology not only simplifies monitoring but also enhances patient engagement in their health management.
About Senseonics and Eversense
Senseonics is dedicated to revolutionizing diabetes care with its Eversense systems, which deliver real-time glucose data and empower users to make informed health decisions. The commitment to patient-centric solutions drives the company to continuously innovate, ensuring that those living with diabetes have access to the best possible resources and technology.
Collaboration with Mercy Healthcare
Furthermore, the event will elaborate on Senseonics’ collaboration with Mercy, a renowned healthcare provider, and emphasize how this partnership enhances patient access to the Eversense 365 system. Their comprehensive healthcare approach has been pivotal in improving patient experiences and outcomes in diabetes management.
Frequently Asked Questions
What is the Eversense 365 system?
The Eversense 365 is a Continuous Glucose Monitoring (CGM) system that allows for continuous glucose tracking for up to one year, providing significant advantages over traditional CGMs.
How can I register for the virtual event?
Interested attendees can register for the event through Senseonics' official communication channels or updates that will be shared in the coming weeks.
Who will be speaking during the event?
The event will feature several key opinion leaders and healthcare professionals specialized in diabetes management, providing valuable insights and expertise.
Is the Eversense 365 system suitable for all diabetes patients?
This system is designed for individuals aged 18 and older with Type 1 and Type 2 diabetes; consulting a healthcare provider is vital to determine individual suitability.
Where can I learn more about Senseonics and their products?
For more information about Senseonics' offerings and the Eversense systems, patients and providers are encouraged to visit Senseonics' official website and their investor relations section.
